Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension
V Croquet, F Moal, N Veal, J Wang, F Oberti, J Roux… - Journal of …, 2002 - Elsevier
Background/Aims: To assess the effects of the early and chronic administration of losartan-a
specific angiotensin II receptor antagonist-in the prevention of hepatic fibrosis and portal
hypertension. Methods/Results:(1) In CCl4 rats, losartan at 5 and 10 mg/kg per day
significantly decreased portal pressure (− 11,− 18%, respectively), splenorenal shunt blood
flow (− 60,− 80%) and liver fibrosis (liver hydroxyproline and area of fibrosis) without
significant changes in mortality and mean arterial pressure (MAP).(2) In bile duct ligated …
specific angiotensin II receptor antagonist-in the prevention of hepatic fibrosis and portal
hypertension. Methods/Results:(1) In CCl4 rats, losartan at 5 and 10 mg/kg per day
significantly decreased portal pressure (− 11,− 18%, respectively), splenorenal shunt blood
flow (− 60,− 80%) and liver fibrosis (liver hydroxyproline and area of fibrosis) without
significant changes in mortality and mean arterial pressure (MAP).(2) In bile duct ligated …